Law Offices of Howard G. Smith announces that it is investigating potential claims on behalf of investors of Lannett Company, Inc. (“Lannett” or the “Company”) (NYSE:LCI). The investigation concerns possible violations of federal securities laws and focuses on Lannett’s business and operations. Lannett develops, manufactures, markets and distributes generic versions of branded pharmaceutical products in the United States. The investigation is related to the Company’s July 16, 2014, announcement that the Company has received interrogatories and subpoena from the State of Connecticut Office of the Attorney General in connection with an investigation into pricing of digoxin − a widely used treatment for congestive heart failure. An article published July 8, 2014, in The New York Times, describes Lannett as the major U.S. supplier of digoxin. According to the Company, the Attorney General’s investigation seeks to determine “whether anyone engaged in any activities that resulted in (a) fixing, maintaining or controlling prices of digoxin or (b) allocating and dividing customers or territories relating to the sale of digoxin in violation of Connecticut antitrust law.” Following this news, Lannett shares declined more than 17 percent in intraday trading on July 16, 2014. If you purchased Lannett shares, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to email@example.com, or visit our website at www.howardsmithlaw.com.